Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ:GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

But, the upshot is that the stock is one of the cheapest in the large-cap biotech and pharma sector, writes Wall Street Journal.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.